After two failed attempts to secure FDA approval, Agile Therapeutics Inc.'s (AGRX) lead product candidate, Twirla, an investigational combined hormonal contraceptive patch, is now all set to face the regulatory agency for the third time on November 16, 2019.
from RTT - Biotech https://ift.tt/2NpG34x
via IFTTT
No comments:
Post a Comment